Skip to content
Search

Latest Stories

RPS urges pharmacy teams to reduce environmental impact of medicines

The Royal Pharmaceutical Society (RPS) has called on industry, pharmacy teams and governments across Great Britain to implement change to reduce the environmental impact of medicines.

To meet this aim, RPS has created a series of policies ahead of COP26 UN Climate Change Conference beginning on October 31.


It noted that medicines are the most widely deployed healthcare intervention and are responsible for 25 per cent of the NHS’s carbon emissions, making pharmacists and pharmacy teams a key player in combat against climate change.

RPS president Claire Anderson said: “The role of the pharmacist and the pharmacy team in preventing illness, optimising medicines and reducing pharmaceutical waste already reduces the impact of medicines on the climate."

She added that pharmacists and pharmacy teams can make a difference by incorporating small changes in the way of working. “Our sustainability policy supports pharmacy teams to pave the way for change and to lead the way in climate action within healthcare.”

For this RPS has listed four areas of focus:

  • Improving prescribing and medicines use
  • Tackling medicines waste
  • Preventing ill health
  • Infrastructure and ways of working

Earlier this month, RPS signed a charter designed to guide effective and high-quality climate action by professional bodies in the UK, and released 'Declaration of Climate and Ecological Emergency' in September.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less